教育背景

2009.09－2012.07    中国药科大学      理学博士

2004.09－2007.07    上海中医药大学    理学硕士

2000.09－2004.07    浙江中医药大学    理学学士

工作经历

2022.01-至今      上海中医药大学中药研究所 研究员，博士生导师

2017.03-2021.12   上海中医药大学中药研究所 副研究员，硕士生导师

2014.06–2019.05   美国希望之城国家医学研究中心博士后

2012.09–2014.05   上海中医药大学中药研究所 博士后

 课题组主要从事中药防治代谢性疾病（肥胖、非酒精性脂肪肝及肝炎、糖尿病和糖尿病并发症等）机制方面的研究。目前主要研究方向包括：（1）中药调控胆汁酸信号通路改善代谢性疾病机制研究；（2）“肠-肝轴”胆汁酸信号通路靶点调控糖脂代谢改善肥胖和代谢性疾病机制研究。研究结果以通讯或第一作者发表在Hepatology, PNAS，Acta Pharmaceutica Sinica B等学术期刊上。

个人荣誉

 2021年度国家自然科学基金优秀青年基金获得者；2017年度上海市浦江学者计划；2021年度上海中医药大学杏林学者。

获奖情况

上海市药学科技二等奖（2017，名列第3位）

2021 CALS Postdoctoral Fellow Research Award（2021）

1. Lili Ding; Qiaoling Yang; Eryun Zhang; Yangmeng Wang; Siming Sun; Yingbo Yang; Tong Tian; Zhengcai Ju; Linshan Jiang; Xunjiang Wang; Zhengtao Wang; Wendong Huang*; Li Yang*; Notoginsenosid e Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and in sulin resistance in mice, Acta Pharmaceutica Sinica B, 2021, 11(6): 1541-1554 (期刊论文)

2. Linshan Jiang; Wei Li; Tongxi Zhuang; Jiejing Yu; Shuai Sun; Zhengcai Ju; Zhengtao Wang; Lili Ding*; Li Yang*; Ginsenoside ro ameliorates high-fat diet–induced obesity and insulin resist ance in mice via activation of the G protein–coupled bile acid receptor 5 pathway, Journal of Pharmacology and Experimental Therapeutics, 2021, 377(3): 441-451 (期刊论文)

3. Lili Ding; Eryun Zhang; Qiaoling Yang; Lihua Jin; Kyle M. Sousa; Bingning Dong; Yangmeng Wang; Jui Tu; Xiaoxiao Ma; Jingyan Tian; Hongli Zhang; Zhipeng Fang; Ana Guan; Yixin Zhang; Zheng tao Wang; David D. Moore*; Li Yang*; Wendong Huang*; Vertical sleeve gastrectomy confers metabolic improvements by reducing intestinal bile acids and lipid absorption in mice, Proceedings of the N ational Academy of Sciences, 2021, 118(6): e2019388118 (期刊论文)

4. Tongxi Zhuang; Wei Li; Li Yang; Zhengtao Wang; Lili Ding*; Mingmei Zhou*; Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications, Frontiers in Pharmacology, 2021, 12:0-731288.

5. Yujie Ma; Jinmei Li; Zhengcai Ju; Wendong Huang; Zhengtao Wang; Li Yang*; Lili Ding*; Danning tablets alleviate high fat diet-induced obesity and fatty liver in mice via modulating SREBP pathway, Journal of Ethnopharmacology, 2021, 279:0-114320.

6. Hui Xue; Luyao Huang; Jui Tu; Lili Ding*; Wendong Huang*; Bile acids and metabolic surgery, Liver Research, 2021, 5(3):164-170.

7. Shenglan Yu; Zhengtao Wang; Lili Ding*; Li Yang*; The regulation of TFEB in lipid homeostasis of non-alcoholic fatty liver disease: Molecular mechanism and promising therapeutic targets, Life Sciences, 2020, 246:117418.

8. Lili Ding; Zhipeng Fang; Yanjun Liu; Eryun Zhang; Tracy Huang; Li Yang; Zhengtao Wang*; Wendong Huang*; Targeting Bile Acid-Activated Receptors in Bariatric Surgery., Handb Exp Pharmacol, 2019, 256: 359-378

9. Lili Ding; Kyle M. Sousa; Lihua Jin; Bingning Dong; Byungwook Kim; Ricardo Ramirez; Zhenz hou Xiao; Ying Gu; Qiaoling Yang; Jie Wang; Donna Yu; Alessio Pigazzi; Dustin Schones; Li Yang; D avid Moore; Zhengtao Wang*; Wendong Huang*; Vertical Sleeve Gastrectomy Activates GPBAR-1/TGR5 to Sustain Weight Loss, Improve Fatty Liver, and Remit Insulin Resistance in Mice, Hepatology, 2016, 64(3): 760-773 (期刊论文)

10. Lili Ding; Li Yang; Zhengtao Wang; Wendong Huang*; Bile acid nuclear receptor FXR and digestive system diseases, Acta Pharmaceutica Sinica B, 2015, 5(2): 135-144 (期刊论文)

1. 杨莉; 王峥涛; 丁丽丽; 张二云 ; 一种三七皂苷Ft1的用途, 2019-12-03, 中国, ZL201711416726.3 (专利)

2. 窦薇; 王峥涛; 张晶晶; 丁丽丽; 孙阿宁; 张二云 ; 三七素的用途, 2017-11-10, 中国, ZL20141001 7982.5 (专利)

3. 王峥涛; 刘青; 丁丽丽; 宋宝亮; 祁萌; 杨莉; 侴桂新 ; 松香型二萜衍生物及其制备方法和应用, 20 17-01-25, 中国, ZL201310482840.1 (专利)

4. 丁丽丽; 刘轩; 杨莉; 王峥涛; 詹常森; 沈丹萍; 王玲; 张正光 ; 大黄素-8-O-β-D-葡萄糖苷在制备保肝利胆药物中的用途, 2014-12-03, 中国, ZL201310113327.5 (专利)

先后主持国家自然科学基金优青项目、国家自然科学基金面上项目、国家自然科学基金青年基金项目、上海市自然科学基金原创探索类项目、上海市浦江人才计划项目等8项，参与国家自然科学基金国际(地区)合作与交流项目等10余项。

担任Frontiers in Endocrinology 杂志评审编辑（Review Editor）；中国药理学通报青年编委、中医药文化青年编委等。